Legal Representation
Attorney
Maury M. Tepper, III
USPTO Deadlines 1 active 1 overdue
| Deadline Type | Event Code | Deadline Date | Days Until | Priority | Extension Available |
|---|---|---|---|---|---|
|
OPPOSITION
Notice of Publication |
NPUB | Nov 14, 2019 | 2062 days overdue | Medium | Until Dec 14, 2019 |
Application History
34 events| Date | Code | Type | Description |
|---|---|---|---|
| May 23, 2025 | NA75 | E | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED |
| May 23, 2025 | C75A | O | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. |
| May 5, 2025 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL |
| Jan 3, 2025 | ES75 | I | TEAS SECTION 71 & 15 RECEIVED |
| Dec 31, 2024 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED |
| May 1, 2020 | FINV | P | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Apr 13, 2020 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB |
| Apr 13, 2020 | FIMP | P | FINAL DISPOSITION PROCESSED |
| Mar 31, 2020 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Dec 31, 2019 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Oct 26, 2019 | GPNX | P | NOTIFICATION PROCESSED BY IB |
| Oct 15, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Oct 15, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Sep 25, 2019 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Sep 25, 2019 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Sep 25, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Aug 20, 2019 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY |
| Aug 8, 2019 | ALIE | A | ASSIGNED TO LIE |
| Jul 29, 2019 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jul 9, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jul 9, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jul 9, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jul 2, 2019 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Jul 2, 2019 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jun 28, 2019 | RFNT | P | REFUSAL PROCESSED BY IB |
| Jun 10, 2019 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Jun 10, 2019 | RFRR | P | REFUSAL PROCESSED BY MPU |
| May 25, 2019 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| May 24, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN |
| May 24, 2019 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| May 20, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| May 20, 2019 | DOCK | D | ASSIGNED TO EXAMINER |
| May 16, 2019 | LIMI | I | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
| May 2, 2019 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 005
[ Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; ] pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; [ pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; ] pharmaceutical preparations for use in ophthalmology [ ; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma ]
Additional Information
Design Mark
The mark consists of eight partially overlapping quadrilaterals organized in pairs and displayed across from each other in a lose formation of a three-dimensional cross; the outer quadrilaterals are magenta, the inner quadrilaterals are green and the overlapping portions are violet.
Color Claim
The color(s) green (3500 c), violet (669 c) and magenta (219 c) is/are claimed as a feature of the mark.
Classification
International Classes
005